Source link : https://www.newshealth.biz/health-news/rucaparib-nivolumab-maintenance-not-the-answer-in-newly-diagnosed-ovarian-cancer/
Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced ovarian cancer, a large randomized trial showed. In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio […]
Author : News Health
Publish date : 2024-09-18 21:44:26
Copyright for syndicated content belongs to the linked Source.
inHealth